Daclatasvir plus Sofosbuvir with or without Ribavirin in patients infected with HCV genotype 3: Interim results of a multicenter compassionate use program in Europe
T Welzel, J Petersen, M Gschwantler, M Cornberg, A Zoufaly, T Berg, U Naumann, M Van der Valk, O Weiland, M Jimenez-Exposito, S Zeuzem · Zeitschrift für Gastroenterologie · 2015 · Heft 08
Bibliografische Angaben
Zusammenfassung
Einleitung: Treatment of HCV genotype 3 (GT3) infection remains a high medical need. Compared to HCV non-GT3, pts with HCV GT3 have faster rates of fibrosis progression, higher prevalence of severe steatosis, and a higher incidence of hepatocellular carcinoma. Treatment options for HCV GT3 pts are limited, and debate continues on the optimal regimen and duration of treatment, especially in those with cirrhosis. This analysis reports interim findings from a compassionate use program (CUP) of Daclastavir (DCV) plus Sofosbuvir (SOF) with or without Ribavirin (RBV) opened in 5 European countries. Material und Method…
